Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Recruiting

Phase 1

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Sponsor:

Bicara Therapeutics

Code:

NCT04429542

Conditions

Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Anal Canal

Colorectal Cancer

Squamous Cell Carcinoma of the Lung

EGFR Amplification

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BCA101

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Bicara Therapeutics on 2025-01-27.